Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimurutamab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Henlius Biotech

    • Most Recent Events

    • 06 Jun 2023 Results evaluating safety of HLX-007 in combination with chemotherapy in patients with advanced solid tumours were presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 26 May 2023 Results presented in a Shanghai Henlius Biotech media release.
    • 26 May 2023 According to a Shanghai Henlius Biotech media release, results from this study were released as online abstract by 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for the first time.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top